Special Issue "Homage to Mark Wainberg"
Deadline for manuscript submissions: closed (31 January 2018)
Dr. Thibault Mesplède
McGill AIDS Centre, Lady Davis Institute for Medical Research at the Jewish General Hospital, 3755 Cote Ste-Catherine Road, Montreal, Quebec, Canada
Interests: HIV drug resistance
Dr. Mark Wainberg was more than an outstanding researcher; he was a great mentor for many, including myself. He was a tireless advocate for the interests of those affected by HIV, whether they lived in Western or developing countries. Mark’s scientific contributions to the field of HIV research are immeasurable, and include, most notably, his work in HIV drug resistance. Most recently, his research focused on integrase inhibitors, including dolutegravir and other second-generation inhibitors. It is worth noting that, with the imminent introduction of integrase inhibitors as part of the standard-of-care in developing countries (dolutegravir being available to hundreds of thousands of individuals in Brazil, Botswana, and other developing countries in 2017), Mark’s work will become exponentially more relevant in the years to come.
After contracting a Dengue virus infection during one of his travels, Mark also turned his scientific attention to emerging viral infections, particularly those involving Flaviviridae. He was indeed a man of boundless scientific curiosity and goodwill.
In this Special Issue, dedicated to Dr. Mark Wainberg’s work, we explore and discuss aspects of HIV infection, transmission, drug resistance and pathogenesis. We also open this Special Issue to manuscripts studying diseases caused by emerging viral infections, keeping in mind that most of recent viral epidemics are imbedded within the same social tissue that has been allowing HIV to thrive for far too long.
Together with the Editors and Publisher, and in accordance with Mark’s deep social convictions, we hope to convey a message of hope and solidarity to researchers of the global South. Accordingly, five investigators from developing countries will benefit from waived publication fees when the work of at least ten investigators is accepted for publication in this Special Issue.
Thibault Mesplède, Ph.D.
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- viral transmission
- viral pathogenesis
- drug resistance